XRHealth has acquired Swing Therapeutics, Inc. for an undisclosed amount. Swing Therapeutics, founded in 2019, specializes in developing digital treatments for disease areas where patients are underserved, particularly autoimmune conditions and chronic overlapping pain conditions (COPCs) such as fibromyalgia, where central pain sensitization is a significant factor. The company has been investing in research to support the development and validation of its pipeline of prescription-based digital therapies, with a near-term goal to bring an FDA-cleared digital program for fibromyalgia to market.
This acquisition strategically expands XRHealth's capabilities within the digital health sector. Swing Therapeutics' focused expertise in tackling complex, chronic conditions through rigorously researched and validated prescription digital therapeutics aligns with the growing demand for evidence-based digital interventions. The integration of Swing's pipeline, particularly its advanced work in fibromyalgia, is expected to broaden XRHealth's therapeutic offerings and address critical unmet needs in patient care.
The acquisition is anticipated to create significant synergies, accelerating the development and market entry of Swing Therapeutics' programs. By combining Swing's specialized research and development efforts with XRHealth's resources, the unified entity aims to enhance innovation in prescription digital therapeutics. This move positions the combined company to deliver a wider array of validated digital treatments, ultimately improving outcomes for patients suffering from chronic and autoimmune conditions.